Bridges A - Search Results

1

Differential protein stability of EGFR mutants determines responsiveness to tyrosine kinase inhibitors.

Ray P, Tan YS, Somnay V, Mehta R, Sitto M, Ahsan A, Nyati S, Naughton JP, Bridges A, Zhao L, Rehemtulla A, Lawrence TS, Ray D, Nyati MK. Ray P, et al. Among authors: bridges a. Oncotarget. 2016 Oct 18;7(42):68597-68613. doi: 10.18632/oncotarget.11860. Oncotarget. 2016. PMID: 27612423 Free PMC article.

2

Disruptin, a cell-penetrating peptide degrader of EGFR: Cell-Penetrating Peptide in Cancer Therapy.

Mehta RK, Shukla S, Ramanand SG, Somnay V, Bridges AJ, Lawrence TS, Nyati MK. Mehta RK, et al. Transl Oncol. 2021 Aug;14(8):101140. doi: 10.1016/j.tranon.2021.101140. Epub 2021 Jun 6. Transl Oncol. 2021. PMID: 34107419 Free PMC article.

3

Drug-development, dose-selection, rational combinations from bench-to-bedside: are there any lessons worth revisiting?

Bridges AJ, Mehta RK, Shukla S, Schipper MJ, Lawrence TS, Nyati MK. Bridges AJ, et al. Oncotarget. 2021 May 25;12(11):1032-1036. doi: 10.18632/oncotarget.27931. eCollection 2021 May 25. Oncotarget. 2021. PMID: 34084277 Free PMC article. No abstract available.

4

Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor.

Gonzales AJ, Hook KE, Althaus IW, Ellis PA, Trachet E, Delaney AM, Harvey PJ, Ellis TA, Amato DM, Nelson JM, Fry DW, Zhu T, Loi CM, Fakhoury SA, Schlosser KM, Sexton KE, Winters RT, Reed JE, Bridges AJ, Lettiere DJ, Baker DA, Yang J, Lee HT, Tecle H, Vincent PW. Gonzales AJ, et al. Among authors: bridges aj. Mol Cancer Ther. 2008 Jul;7(7):1880-9. doi: 10.1158/1535-7163.MCT-07-2232. Epub 2008 Jul 7. Mol Cancer Ther. 2008. PMID: 18606718

5

Chemical inhibitors of protein kinases.

Bridges AJ. Bridges AJ. Chem Rev. 2001 Aug;101(8):2541-72. doi: 10.1021/cr000250y. Chem Rev. 2001. PMID: 11749388 Review. No abstract available.

6

Inhibitors of protein tyrosine kinases.

Fry DW, Bridges AJ. Fry DW, et al. Among authors: bridges aj. Curr Opin Biotechnol. 1995 Dec;6(6):662-7. doi: 10.1016/0958-1669(95)80109-x. Curr Opin Biotechnol. 1995. PMID: 8527837 Review.

7

Enantioselective inhibition of the epidermal growth factor receptor tyrosine kinase by 4-(alpha-phenethylamino)quinazolines.

Bridges AJ, Cody DR, Zhou H, McMichael A, Fry DW. Bridges AJ, et al. Bioorg Med Chem. 1995 Dec;3(12):1651-6. doi: 10.1016/0968-0896(95)00149-2. Bioorg Med Chem. 1995. PMID: 8770389

8

Anticancer efficacy of the irreversible EGFr tyrosine kinase inhibitor PD 0169414 against human tumor xenografts.

Vincent PW, Bridges AJ, Dykes DJ, Fry DW, Leopold WR, Patmore SJ, Roberts BJ, Rose S, Sherwood V, Zhou H, Elliott WL. Vincent PW, et al. Among authors: bridges aj. Cancer Chemother Pharmacol. 2000;45(3):231-8. doi: 10.1007/s002800050034. Cancer Chemother Pharmacol. 2000. PMID: 10663641

9

A specific inhibitor of the epidermal growth factor receptor tyrosine kinase.

Fry DW, Kraker AJ, McMichael A, Ambroso LA, Nelson JM, Leopold WR, Connors RW, Bridges AJ. Fry DW, et al. Among authors: bridges aj. Science. 1994 Aug 19;265(5175):1093-5. doi: 10.1126/science.8066447. Science. 1994. PMID: 8066447

10

Tyrosine kinase inhibitors. 8. An unusually steep structure-activity relationship for analogues of 4-(3-bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor.

Bridges AJ, Zhou H, Cody DR, Rewcastle GW, McMichael A, Showalter HD, Fry DW, Kraker AJ, Denny WA. Bridges AJ, et al. J Med Chem. 1996 Jan 5;39(1):267-76. doi: 10.1021/jm9503613. J Med Chem. 1996. PMID: 8568816

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

510 results

Search Page